Single agent and synergistic activity of the "first in class" dual PI3K/BRD4 inhibitor SF1126 with Sorafenib in hepatocellular carcinoma
Singh, A. R., Joshi, S., Burgoyne, A. M., Sicklick, J. K., Ikeda, S., Kono, Y., Garlich, J. R., Morales, G. A., Durden, D. L.Language:
english
Journal:
Molecular Cancer Therapeutics
DOI:
10.1158/1535-7163.MCT-15-0976
Date:
August, 2016
File:
PDF, 9.92 MB
english, 2016